Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure

Rhea-AI Summary

Carlsmed (Nasdaq: CARL) announced the first posterior lumbar spine surgery using its aprevo® Lumbar Bi-lateral Posterior System, performed Feb. 10, 2026 at University of Colorado Hospital.

The company says the procedure demonstrates aprevo® integration across lumbar fusion approaches and expects a full commercial launch later in 2026.

Positive

• First-ever Bi-lateral posterior lumbar interbody fusion performed with aprevo®
• Company plans a full commercial launch of the system later in 2026
• aprevo® system integrates AI-enabled planning across additional lumbar fusion approaches

Negative

• Clinical evidence limited to a single reported procedure to date
• No clinical outcome metrics or comparative data disclosed with the announcement

News Market Reaction – CARL

-0.08%

2 alerts

-0.08% Session close to close

+5.1% Peak Tracked

-8.6% Trough Tracked

$336.13M Market Cap

1.0x Rel. Volume

In the Feb 10 session, CARL declined 0.08%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.1% during that session. Argus tracked a trough of -8.6% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement adds the first aprevo® bi-lateral posterior lumbar interbody fusion procedure to C...

Analysis

This announcement adds the first aprevo® bi-lateral posterior lumbar interbody fusion procedure to Carlsmed’s personalized spine surgery portfolio, extending its AI-enabled aprevo® platform into another lumbar approach. Recent history included strong 2025 revenue growth and supportive lumbar outcomes data, suggesting an ongoing focus on clinical validation and commercial expansion. Investors may watch for the timing and adoption of the full commercial launch later this year and how new procedures contribute to overall platform utilization.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 12	Preliminary 2025 revenue	Positive	+13.8%	Strong preliminary Q4 and full-year 2025 revenue growth and user expansion.
Jan 06	Clinical study data	Positive	+2.9%	Published 2-year lumbar data showing reduced mechanical-complication revisions with aprevo®.
Dec 16	Conference participation	Neutral	+0.0%	Planned presentation and investor meetings at J.P. Morgan 2026 Healthcare Conference.
Dec 03	Cervical platform launch	Positive	+12.4%	U.S. commercial launch of aprevo® cervical technology platform and early case experience.
Nov 19	Conference participation	Neutral	-0.2%	Participation in Piper Sandler healthcare conference with investor meetings and webcast.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive product and data news has often coincided with positive price reactions for CARL.

Recent Company History

Over the past few months, Carlsmed reported strong preliminary growth for 2025 with revenue of $15.2M in Q4 and $50.5M for the year, alongside rapid surgeon adoption. Clinical data published in Global Spine Journal showed reduced revision rates with aprevo® lumbar implants, and the company launched its cervical fusion platform in the U.S. while participating in major healthcare conferences. Today’s announcement of the first aprevo® bi-lateral posterior lumbar fusion procedure extends this pattern of platform and clinical-expansion updates.

Key Terms

posterior lumbar interbody fusion, lumbar fusion, pre-operative, intra-operative, +4 more

8 terms

posterior lumbar interbody fusion medical

"The addition of the aprevo® Bi-lateral Posterior Lumbar Interbody Fusion procedure..."

A posterior lumbar interbody fusion is a type of spine surgery that joins two or more lower-back vertebrae by removing the damaged disc and placing a spacer and implants from the back of the spine, allowing bone to grow and fuse the segments together. For investors, it signals demand for surgical implants, tools, and hospital services and can affect market revenue, device approval importance, and reimbursement trends—think of it as “welding” two faulty pieces of a load-bearing structure.

lumbar fusion medical

"extending its use across additional lumbar fusion approaches allows me to more precisely..."

Lumbar fusion is a surgical procedure that permanently joins two or more bones in the lower spine to stop painful motion, typically using bone material and metal implants to encourage the bones to grow together. For investors, it matters because it creates steady demand for spinal implants, surgical equipment, hospital services and rehabilitation; outcomes, complication rates and reimbursement policies directly affect device makers, hospitals and insurers—like welding two moving parts to stop a squeak but changing how the machine works.

pre-operative medical

"integral to my pre-operative, intra-operative, and post-operative workflow..."

The period and set of actions that take place immediately before a surgical operation, including medical evaluations, lab tests, imaging, patient instructions and logistical planning to make the procedure safe and possible. Investors should care because pre-operative activity drives demand for diagnostics, staffing, supplies and short‑term revenue, and can affect procedure timing, costs and complication risk — like checking a car and packing tools before a long trip to avoid delays or costly repairs.

intra-operative medical

"integral to my pre-operative, intra-operative, and post-operative workflow..."

Intra-operative describes anything that occurs or is used during a surgical operation — for example devices, monitoring, imaging or medications applied while the surgeon is working. For investors, the term signals when a product or service is used in the care pathway, which affects adoption rates, regulatory requirements, hospital purchasing decisions and potential revenue because tools used during surgery are often bought, reimbursed and deployed differently than those used before or after the procedure; think of it like the specialized tools a mechanic uses while the engine is open.

post-operative medical

"integral to my pre-operative, intra-operative, and post-operative workflow..."

The period after a surgical operation when a patient recovers and is monitored for healing, complications, pain control, and rehabilitation. For investors, post-operative outcomes drive demand for medical devices, drugs, hospital services and follow-up care, affect costs and reimbursement, and influence regulatory and liability risk—think of it like a product’s warranty and aftercare period that determines whether extra support or fixes are needed.

ai-enabled technical

"our personalized, AI-enabled approach to spine surgery..."

AI-enabled describes a product, service, or process that uses artificial intelligence—software that learns from data and makes decisions or predictions—as a core feature rather than a minor add-on. For investors it matters because AI-enabled offerings can boost productivity, lower costs or unlock new revenue streams; like adding a smart autopilot to a routine task, they can change a company's growth potential and competitive edge while also bringing higher upfront investment needs and distinct regulatory or ethical risks.

clinical intelligence medical

"combines proprietary AI-enabled software and clinical intelligence to deliver..."

Clinical intelligence is the collection and analysis of medical and patient data to reveal patterns that help clinicians, researchers, and managers make better decisions—think of it as a smart dashboard that turns messy health records into clear, actionable insights. Investors care because it can speed drug development, improve healthcare operations, lower costs, and create competitive products or services that drive revenue and reduce regulatory or commercial risk.

preoperative planning medical

"deliver personalized surgical strategies and preoperative planning across a range..."

A detailed process surgeons and care teams use to map out a patient's operation before entering the operating room, covering steps, tools, imaging, and contingency plans. For investors, robust preoperative planning signals lower surgical risk, more efficient use of devices and staff, and higher chances of successful outcomes and faster adoption of related products or services—much like a well-prepared travel itinerary reduces delays and surprises on a trip.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo^® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado.

“This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions designed to help surgeons plan with greater precision, improve patient outcomes, and reduce costly revisions. The addition of the aprevo^® Bi-lateral Posterior Lumbar Interbody Fusion procedure to our personalized surgery procedure portfolio further demonstrates the power and versatility of our personalized, AI-enabled approach to spine surgery,” said Mike Cordonnier, Chairman and CEO of Carlsmed. “We look forward to our full commercial launch this year to provide this personalized procedural option to patients, surgeons, and hospital systems on a larger scale.”

“Carlsmed’s aprevo^® technology is integral to my pre-operative, intra-operative, and post-operative workflow, and extending its use across additional lumbar fusion approaches allows me to more precisely tailor treatment to each patient,” said Dr. Kleck. “Being able to personalize procedures based on each patient’s anatomy and pathology gives me greater confidence in achieving alignment goals. Adding a Bi-lateral posterior system to the list of procedures addressable with aprevo^® will enable me to utilize this technology across a broader range of patients.”

Carlsmed’s Bi-lateral Posterior Fusion System integrates seamlessly with the Company’s broader aprevo^® platform technology, which combines proprietary AI-enabled software and clinical intelligence to deliver personalized surgical strategies and preoperative planning across a range of spinal pathologies. The Company expects to commercially launch the system later this year.

About Carlsmed 
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects, including statements about the timing of the commercial launch of the Company’s Bi-Lateral Posterior Fusion System, the potential of the Company’s products, the ability of the Company’s products to improve patient outcomes and reduce revision surgeries, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “likely,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including such important factors as are set forth under the caption “Risk Factors” in Carlsmed’s Registration Statement on Form S-1 on file with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Carlsmed’s views as of the date of this press release. Carlsmed anticipates that subsequent events and developments will cause its views to change. However, while Carlsmed may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Carlsmed’s views as of any date subsequent to the date of this press release.

Investor Relations 
Caroline Corner, PhD
IR@Carlsmed.com 

Media 
LeAnn Burton 
Senior Director Brand Marketing 
LBurton@Carlsmed.com 

FAQ

What did Carlsmed (CARL) announce on Feb. 10, 2026 about aprevo®?

Carlsmed announced the first posterior lumbar surgery using its aprevo® Bi-lateral Posterior System. According to the company, the procedure was performed at University of Colorado Hospital and demonstrates aprevo® applied to another lumbar fusion approach.

When does Carlsmed (CARL) expect to commercialize the aprevo® Bi-lateral Posterior System?

Carlsmed expects a full commercial launch of the system later in 2026. According to the company, the launch will make the personalized procedural option available to patients, surgeons, and hospital systems at larger scale.

Who performed the first aprevo® Bi-lateral Posterior Lumbar Interbody Fusion using CARL technology?

The first procedure was performed by orthopedic spine surgeon CJ Kleck, M.D. at University of Colorado Hospital. According to the company, Dr. Kleck used aprevo® in his pre-, intra-, and post-operative workflow.

How does aprevo® integrate into spine surgery according to Carlsmed (CARL)?

aprevo® combines proprietary AI-enabled software and clinical intelligence for personalized surgical strategies and preoperative planning. According to the company, the Bi-lateral Posterior Fusion System integrates seamlessly with the broader aprevo® platform.

What investor implications does Carlsmed's first aprevo® Bi-lateral Posterior procedure have for CARL shareholders?

The milestone signals product development progress and potential commercial expansion later in 2026. According to the company, this expands aprevo® addressable procedures, though no revenue, pricing, or market-size figures were provided.